Bodal Chemicals Board Approves Q2/H1 FY26 Results and Sale of Inoperative Units
Bodal Chemicals announced Q2/H1 FY26 results with improved half-year performance and approved the sale of inoperative units, generating significant profit from asset divestment and settling an insurance claim.
The announcement includes both the routine disclosure of quarterly financial results and a strategic decision to sell non-performing assets. While the quarterly profit saw a sequential decline, the half-year performance showed significant improvement year-on-year, and the asset sale provides capital and streamlines operations, making the overall impact medium.
The company reported a substantial year-on-year improvement in half-year consolidated and standalone profits. The strategic divestment of inoperative units generated significant non-operating income, contributing positively to the overall financial health and asset optimization. The insurance claim settlement also provides financial relief.
* The Board of Directors of Bodal Chemicals Limited met on November 12, 2025, and approved the standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2025. * The Board also approved the sale of Unit-II, located at Plot No: 123-124, Phase-I, G.I.D.C., Vatva, Ahmedabad. This unit was inoperative for a long time and was not significant in terms of revenue or other matters for the company. The sale will be at prevailing market rates, with the selling price not substantial compared to the company's size. * Consolidated Financial Highlights (Q2 FY26 vs Q1 FY26): * Revenue from operations increased to ₹480.45 crore from ₹454.20 crore. * Profit for the period decreased to ₹5.99 crore from ₹9.53 crore. * Basic Earnings Per Share (EPS) for Q2 was ₹0.47, down from ₹0.76. * Consolidated Financial Highlights (H1 FY26 vs H1 FY25): * Revenue from operations increased to ₹934.66 crore from ₹854.09 crore. * Profit for the period was ₹15.53 crore, a significant improvement from a loss of ₹1.42 crore in H1 FY25. * Basic EPS for H1 was ₹1.23, up from a loss of ₹0.11 in H1 FY25. * Standalone Financial Highlights (Q2 FY26 vs Q1 FY26): * Revenue from operations increased to ₹471.96 crore from ₹444.85 crore. * Profit for the period decreased to ₹4.20 crore from ₹10.14 crore. * Basic EPS for Q2 was ₹0.33, down from ₹0.82. * Standalone Financial Highlights (H1 FY26 vs H1 FY25): * Revenue from operations increased to ₹916.80 crore from ₹846.41 crore. * Profit for the period was ₹14.07 crore, up from ₹1.73 crore in H1 FY25. * Basic EPS for H1 was ₹1.15, up from ₹0.14 in H1 FY25. * During the quarter, the company received an insurance claim of ₹4.71 crore against a total claim of ₹5.99 crore for a fire incident in December 2024 at Unit 7. The balance of ₹0.30 million (₹30 lakh) was booked as an exceptional item. * The sale of part of Unit-II generated a profit of ₹10.66 crore, and the sale of Unit-III generated a profit of ₹7.23 crore, both included in Other Income for the quarter.
What to do with a filing like this
Bodal Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bodal Chemicals Limited. Read the original for the full detail.